@FierceBiotech: Brain switch turns 'on' when danger hits, 'off' when threat passes. Item | Follow @FierceBiotech
@JohnCFierce: MDV3100 release this a.m. includes new survey on specialists, desire for new prostate cancer drugs. Release | Follow @JohnCFierce
@RyanMFierce: Help me find the world's smartest biotech techies for new Fierce special report: Report | Follow @RyanMFierce
@FierceMedDev: AngioDynamics' new chief playing offense and ready for risk. Via @Business_Review. Article | Follow @FierceMedDev
>Takeda is offering up late-stage data showing its diabetes drug TAK-875 reduced blood sugar just as well as a generic, but with fewer side effects. Only 2% of the patients taking the experimental drug developed hypoglycemia, compared with 19% in the generic arm. Story
> The Los Angeles Times covers new efforts by GTx and Helsinn to develop treatments for cachexia, the loss of muscle and weight among patients suffering from cancer. Report
> Burrill veteran Ann Hanham tells the Globe and Mail that she's out trying to raise a $200 million fund to invest in Canada's biotech companies. "It is heartbreaking that so much talent and so much brilliant research isn't being commercialized," she tells the newspaper. Story
> Affymax says it has earned a $5 million milestone from Takeda. Story
> With an eye to developing the market for the promising prostate cancer drug MDV3100, Medivation cites a new survey showing that virtually all the practitioners in the field see the need for new therapies. Release
Pharma News
@FiercePharma: Glenmark pulls 7 lots of contraceptive pills on a packaging error that could cause incorrect dosing/pregnancy risk. Article | Follow @FiercePharma
Medical Devices News
> Autonomic tackles migraines with neurostimulation tech. Article
> InSightec scores $13.75M from GE. Story
> Wright sees quarterly sales, net income drop. News
> Can U.S. ensure access to a 2nd diagnostic test? Item
IT News
> Roche getting entire workforce to use Google Apps. Story
> Startup aims to tap wisdom of the crowd for low-cost drug trials. Article
> J&J hires Selventa to build computerized models for personalized medicine. News
> Algorithm may expose drug targets for Alzheimer's. More
> OmniComm licenses clinical trials software to CRO Pharma Medica. Item
And Finally… Scientists at MIT and the Ragon Institute believe that a software program used to track stock prices could be a valuable tool in discovering a vaccine for HIV. Story